Lansoprazole
- Generic Name
- Lansoprazole
- Brand Names
- Prevacid, Prevpac
- Drug Type
- Small Molecule
- Chemical Formula
- C16H14F3N3O2S
- CAS Number
- 103577-45-3
- Unique Ingredient Identifier
- 0K5C5T2QPG
- Background
Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other patholog...
- Indication
Lansoprazole is used to reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (NSAID) induced gastric and duodenal ulcers. It may be used in the maintenance and healing of sever...
- Associated Conditions
- Duodenal Ulcer, Erosive Esophagitis, Helicobacter Pylori Infection, Symptomatic Gastroesophageal Reflux Disease (sGERD), Ulcer Healing, Zollinger-Ellison Syndrome, Active Duodenal ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Maintenance of healing Erosive esophagitis
- Associated Therapies
- -
Intraluminal Therapy for Helicobacter Pylori Infection
- Conditions
- Interventions
- First Posted Date
- 2017-04-21
- Last Posted Date
- 2018-05-02
- Lead Sponsor
- Mackay Memorial Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03124420
- Locations
- 🇨🇳
Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan, Taipei, Taiwan
Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection
- Conditions
- Interventions
- First Posted Date
- 2017-02-10
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 234
- Registration Number
- NCT03050307
- Locations
- 🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Yijishan hospital of Wan nan Medical college, Wuhu, Anhui, China
🇨🇳Beijing Chao Yang Hospital, Beijing, Beijing, China
Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection
- Conditions
- Interventions
- First Posted Date
- 2017-02-10
- Last Posted Date
- 2020-06-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 533
- Registration Number
- NCT03050359
- Locations
- 🇨🇳
Shiyan Taihe Hospital, Shiyan, Hebei, China
🇨🇳Jiangxi Nanchang 3rd Hospital, Nanchang, Jiangxi, China
🇰🇷Korea University Ansan Hospital, Ansan-si, Gyeonggi-do, Korea, Republic of
TAK-438 Bismuth Drug Interaction Study
- Conditions
- Interventions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 30
- Registration Number
- NCT02892409
Efficacy and Safety of Dexlansoprazole in Healing and Maintaining Healing of Erosive Esophagitis
- Conditions
- Interventions
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2019-02-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 37
- Registration Number
- NCT02873702
- Locations
- 🇨🇳
Binzhou Medical University Hospital, Binzhou, Shandong, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Chongqing Three Gorges Central Hospital, Chong Qing, Chong Qing, China
Treatment Effect Between Dexlansoprazole and Double-dose Lansoprazole in Obesity Patients With Reflux Esophagitis
- Conditions
- Interventions
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2016-05-03
- Lead Sponsor
- National Cheng-Kung University Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT02759393
A Study to Evaluate REbamiPide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis
- Conditions
- Interventions
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2016-04-29
- Lead Sponsor
- YongChan Lee
- Target Recruit Count
- 143
- Registration Number
- NCT02755753
- Locations
- 🇰🇷
Soonchunhyang University Bucheon Hospital, Bucheon, Korea, Republic of
🇰🇷Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
🇨🇳Yang Shiming, Chongqing, Chongqing, China
Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety
- First Posted Date
- 2016-02-10
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 208
- Registration Number
- NCT02679508
- Locations
- 🇯🇵
Tokatsu Tsujinaka Hospital, Abiko, Chiba, Japan
🇯🇵Hakodate Hospital, Hakodate, Hokkaido, Japan
🇯🇵Shiga University Of Medical Science Hospital, Otsu, Shiga, Japan
Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Clarithromycin Quadruple Therapy
- Conditions
- Interventions
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Xijing Hospital of Digestive Diseases
- Target Recruit Count
- 566
- Registration Number
- NCT02633930
- Locations
- 🇨🇳
Xijing Hospital of Digestive Diseases, Xi'an, Shanxi, China
🇨🇳Xijing Hospital of Digestive Disease, Xi'an, Shanxi, China
A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2015-12-09
- Last Posted Date
- 2018-01-08
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT02625259
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.